SCHEMBL3878422

SCHEMBL3878422

CCC(C)C(=O)N(C)Cc1cccc(C(F)(F)F)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TACR1 P25103 2/20 0.53
HPGD P15428 1/20 0.49
EPHX1 P07099 4/20 0.48
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
HTR2A P28223 2/20 0.48
HTR2B P41595 2/20 0.48
HTR2C P28335 1/20 0.48
SLC6A4 P31645 2/20 0.47
SLC6A2 P23975 1/20 0.47
PTGES O14684 1/20 0.47
SIGMAR1 Q99720 1/20 0.46
LMNA P02545 1/20 0.46
MAPT P10636 1/20 0.46
ADRA2C P18825 1/20 0.46
ADRA1A P35348 1/20 0.46
DRD3 P35462 1/20 0.46
OPRK1 P41145 1/20 0.46
KDM4E B2RXH2 1/20 0.46
CETP P11597 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3885499 0.83 HPGD (0.50) TACR1HPGDMEN1KMT2ASLC6A4
SCHEMBL29565828 0.81 TACR1 (0.53) TACR1EPHX1MEN1KMT2ASLC6A4
SCHEMBL6410982 0.80 HDAC6 (0.56) TACR1EPHX1MEN1KMT2AHTR2A
SCHEMBL21392795 0.77 TACR1 (0.52) TACR1EPHX1MEN1KMT2ASLC6A4
SCHEMBL3882782 0.76 MLYCD (0.56) TACR1HPGDMEN1KMT2AHTR2A
SCHEMBL14438325 0.74 HTR2A (0.58) EPHX1MEN1KMT2AHTR2AHTR2B
SCHEMBL11282361 0.74 EPHX1 (0.51) EPHX1MEN1KMT2AHTR2AHTR2B
SCHEMBL27684532 0.73 HDAC6 (0.50) EPHX1MEN1KMT2APTGESCETP
SCHEMBL4243270 0.73 HTR2A (0.56) MEN1KMT2AHTR2AHTR2BHTR2C
SCHEMBL7612638 0.73 HTR2A (0.66) EPHX1MEN1KMT2AHTR2AHTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7592345-B2 Piperazine and [1,4]diazepan derivatives as NK antagonists HOFFMANN-LA ROCHE INC. (US) 2009-09-22 US disclosed
US-20080312216-A1 PIPERAZINE AND [1,4]DIAZEPAN DERIVATIVES AS NK ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2008-12-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312216-A1 PIPERAZINE AND [1,4]DIAZEPAN DERIVATIVES AS NK ANTAGONISTS DRD3, KCND3, GRIN3A TACR1 21/4885HPGD 2069/4885EPHX1 2205/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.